{"id":"NCT04145531","sponsor":"Jazz Pharmaceuticals","briefTitle":"An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)","officialTitle":"An Open-Label, Multicenter Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coli-derived Asparaginases","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-12-27","primaryCompletion":"2022-07-13","completion":"2022-07-13","firstPosted":"2019-10-30","resultsPosted":"2023-11-18","lastUpdate":"2023-11-18"},"enrollment":229,"design":{"allocation":"NA","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Leukemia"],"interventions":[{"type":"DRUG","name":"IM JZP-458","otherNames":[]},{"type":"DRUG","name":"IV JZP-458","otherNames":[]}],"arms":[{"label":"JZP-458","type":"EXPERIMENTAL"}],"summary":"This is an open-label, multicenter, dose confirmation, and PK study of JZP-458 in patients (of any age) with ALL/LBL who are hypersensitive to E. coli-derived asparaginases (allergic reaction or silent inactivation). This study is designed to assess the tolerability and efficacy of JZP-458 (only in patients who develop hypersensitivity to an E. coli-derived asparaginase), as measured by asparaginase activity.","primaryOutcome":{"measure":"Response Rate During the First Course of JZP-458 Administration","timeFrame":"Baseline up to 2 weeks","effectByArm":[{"arm":"Part A: JZP-458 IM 25 mg/m^2 (MWF)","deltaMin":18,"sd":null},{"arm":"Part A: JZP-458 IM 37.5 mg/m^2 (MWF)","deltaMin":70,"sd":null},{"arm":"Part A: JZP-458 IM 25 (MW)/50 mg/m^2 (F)","deltaMin":44,"sd":null},{"arm":"Part B: JZP-458 IV 25 (MW)/50 mg/m^2 (F)","deltaMin":20,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":74,"countries":["United States","Canada"]},"refs":{"pmids":["36108304","39454281"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":33},"commonTop":["Anaemia","Vomiting","Platelet count decreased","Neutrophil count decreased","Nausea"]}}